Evidence map›Paper›PMID 38702437›Full record

ArticleScientific reports2024

Clinical impact of high-quality testing for peritoneal lavage cytology in pancreatic cancer.

Masahiro Tanemura, Kenta Furukawa, Manabu Mikamori, Tadafumi Asaoka, Hironao Yasuoka, Daiki Marukawa, Yasuo Urata, Daisaku Yamada, Shogo Kobayashi, Hidetoshi Eguchi

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Masahiro TanemuraDepartment of Surgery, Rinku General Medical Center, 2-23 Rinku Orai-kita, Izumisano, Osaka, 598-8577, Japan. mtanemuram64@gmail.com.
Kenta FurukawaDepartment of Surgery, Osaka Police Hospital, 10-31 Kitayamachyo, Tennouji-ku, Osaka, 543-0035, Japan.
Manabu MikamoriDepartment of Surgery, Osaka Police Hospital, 10-31 Kitayamachyo, Tennouji-ku, Osaka, 543-0035, Japan.
Tadafumi AsaokaDepartment of Surgery, Osaka Police Hospital, 10-31 Kitayamachyo, Tennouji-ku, Osaka, 543-0035, Japan.
Hironao YasuokaDepartment of Pathology, Osaka Police Hospital, 10-31 Kitayamachyo, Tennouji-ku, Osaka, 543-0035, Japan.
Daiki MarukawaDepartment of Surgery, Rinku General Medical Center, 2-23 Rinku Orai-kita, Izumisano, Osaka, 598-8577, Japan.
Yasuo UrataOncolys BioPharma Inc., Toranomon Towers 10F, 4-1-28 Toranomon, Minato-ku, Tokyo, 105-0001, Japan.
Daisaku YamadaDepartment of Gastroenterological Surgery, Graduate School of Medicine and Faculty of Medicine, Osaka University, 2-2 Yamadaoka, Suita, Osaka, 565-0871, Japan.
Shogo KobayashiDepartment of Gastroenterological Surgery, Graduate School of Medicine and Faculty of Medicine, Osaka University, 2-2 Yamadaoka, Suita, Osaka, 565-0871, Japan.
Hidetoshi EguchiDepartment of Gastroenterological Surgery, Graduate School of Medicine and Faculty of Medicine, Osaka University, 2-2 Yamadaoka, Suita, Osaka, 565-0871, Japan.

Funding

Ministry of Education, Sports and Culture of Japan 22K08799
6 · The paper itself

Abstract

In pancreatic ductal adenocarcinoma (PDAC) patients, the importance of peritoneal lavage cytology, which indicates unresectability, remains controversial. This study sought to determine whether positive peritoneal lavage cytology (CY+) precludes pancreatectomy. Furthermore, we propose a novel liquid biopsy using peritoneal lavage fluid to detect viable peritoneal tumor cells (v-PTCs) with TelomeScan F35, a telomerase-specific replication-selective adenovirus engineered to express green fluorescent protein. Resectable cytologically or histologically proven PDAC patients (n = 53) were enrolled. CY was conducted immediately following laparotomy. The resulting fluid was examined by conventional cytology (conv-CY; Papanicolaou staining and MOC-31 immunostaining) and by the novel technique (Telo-CY; using TelomeScan F35). Of them, 5 and 12 were conv-CY+ and Telo-CY+, respectively. All underwent pancreatectomy. The two double-CY+ (conv-CY+ and Telo-CY+) patients showed early peritoneal recurrence (P-rec) postoperatively, despite adjuvant chemotherapy. None of the three conv-CY+ Telo-CY- patients exhibited P-rec. Six of the 10 Telo-CY+ conv-CY- patients (60%) relapsed with P-rec. Of the remaining 38 double-CY- [conv-CY-, Telo-CY-, conv-CY± (Class III)] patients, 3 (8.3%) exhibited P-rec. Although conv-CY+ status predicted poor prognosis and a higher risk of P-rec, Telo-CY was more sensitive for detecting v-PTC. Staging laparoscopy and performing conv-CY and Telo-CY are needed to confirm the indication for pancreatectomy.

Indexed as

Carcinoma, Pancreatic DuctalPancreatectomyPancreatic NeoplasmsPeritoneal LavageAdultAgedAged, 80 and overCytodiagnosisFemaleHumansLiquid BiopsyMaleMiddle AgedNeoplasm Recurrence, LocalPeritoneal NeoplasmsLiquid biopsyOccult metastasisPancreatic cancerPeritoneal lavage cytologyPeritoneal recurrenceStaging laparoscopy

Identifiers

PMID38702437
PMCPMC11068862

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.